| |
PRZOOM - /newswire/ -
Farmington, CT, United States, 2011/08/01 - New World Vaccines Market report by Visiongain provides market outlooks, sales and revenue forecasts for leading vaccine brands.
|
| |
Global Information Inc. presents a new market research report,“World Vaccines Market 2011-2021“ by Visiongain.
According to Visiongain, GlaxoSmithKline vaccines, such as Infanrix/Pediarix, are in position to achieve high growth rates in emerging markets where vaccination rates are growing rapidly. The market for pediatric combination vaccines is currently dominated by GlaxoSmithKline and Sanofi Pasteur. GlaxoSmithKline’s Infanrix and Pediarix face strong competition from Sanofi’s Pentacel, Pediacel, Repevax and Tetravac. Even so, Visiongain believes GlaxoSmithKline vaccines will be able to hold off the competition from Sanofi and others as they move forward in the new emerging markets. The report estimates that sales for Infanrix will reach $1565 and a compound annual growth rate (CAGR) of 6.7% through 2015. Sales will rise at a CAGR of 5.6% to $2065m by the end of the forecast period in 2021.
In addition to paediatric (or pediatric) vaccines, the report also discusses and provides grouped forecasts for influenza vaccines, prophylactic vaccines, and therapeutic vaccines. Commercial prospects are outlined for the following vaccine manufacturers: GlaxoSmithKline (GSK), Sanofi Pasteur, Merck & Co., Novartis and Pfizer. The report shows revenue forecasts to 2021 for leading vaccines brands and products including Prevnar, Pandemrix, Fluzone, Proquad, MMR-II, Varivax, Infanrix, Pediarix and Gardsil.
For more information, please visit giiresearch.com or email Press[.]gii.co.jp
Global Information Inc. (GII) is a leading worldwide distributor of market research.
|
press[.]gii.co.jp 
